A Phase I/II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Patients With BRAF Wildtype Metastatic Melanoma

Trial Profile

A Phase I/II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Patients With BRAF Wildtype Metastatic Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Nintedanib (Primary) ; Paclitaxel
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms NIPAWILMA
  • Most Recent Events

    • 19 Jan 2015 Status changed from not yet recruiting to recruiting, according to European Clinical Trials Database record.
    • 24 Dec 2014 The trial focus of study has been changed from TU, AR to TU as maximum tolerated dose has been removed from primary endpoints section, as per ClinicalTrials.gov record.
    • 09 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top